[go: up one dir, main page]

DK2854910T3 - Ceramidniveauer i behandling og forebyggelse af infektioner - Google Patents

Ceramidniveauer i behandling og forebyggelse af infektioner Download PDF

Info

Publication number
DK2854910T3
DK2854910T3 DK13797635.3T DK13797635T DK2854910T3 DK 2854910 T3 DK2854910 T3 DK 2854910T3 DK 13797635 T DK13797635 T DK 13797635T DK 2854910 T3 DK2854910 T3 DK 2854910T3
Authority
DK
Denmark
Prior art keywords
ceramid
infections
prevention
levels
treatment
Prior art date
Application number
DK13797635.3T
Other languages
English (en)
Inventor
Edward H Schuchman
Erich Gulbins
Anthony Futerman
Yael Pewzner-Jung
Original Assignee
Icahn School Med Mount Sinai
Yeda Res And Development Co Ltd At The Weizmann Institute Of Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai, Yeda Res And Development Co Ltd At The Weizmann Institute Of Science filed Critical Icahn School Med Mount Sinai
Application granted granted Critical
Publication of DK2854910T3 publication Critical patent/DK2854910T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK13797635.3T 2012-06-01 2013-05-31 Ceramidniveauer i behandling og forebyggelse af infektioner DK2854910T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654519P 2012-06-01 2012-06-01
PCT/US2013/043608 WO2013181530A1 (en) 2012-06-01 2013-05-31 Ceramide levels in the treatment and prevention of infections

Publications (1)

Publication Number Publication Date
DK2854910T3 true DK2854910T3 (da) 2020-05-04

Family

ID=49673925

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13797635.3T DK2854910T3 (da) 2012-06-01 2013-05-31 Ceramidniveauer i behandling og forebyggelse af infektioner

Country Status (14)

Country Link
US (5) US9492514B2 (da)
EP (2) EP3679923B1 (da)
JP (5) JP6369814B2 (da)
CN (2) CN104582770B (da)
CA (1) CA2874146C (da)
DK (1) DK2854910T3 (da)
ES (2) ES2786128T3 (da)
HR (1) HRP20200661T1 (da)
HU (1) HUE051020T2 (da)
LT (1) LT2854910T (da)
PL (1) PL2854910T3 (da)
PT (1) PT2854910T (da)
SI (1) SI2854910T1 (da)
WO (1) WO2013181530A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2013036875A1 (en) 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation
EP3679923B1 (en) * 2012-06-01 2021-08-04 Icahn School of Medicine at Mount Sinai Ceramide levels in the treatment and prevention of infections
EP3659619A1 (en) * 2013-03-14 2020-06-03 Icahn School of Medicine at Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
ES2673276T3 (es) 2013-03-14 2018-06-21 University Of Ottawa Métodos para el diagnóstico y el tratamiento de la enfermedad inflamatoria intestinal
WO2016049772A1 (en) 2014-10-03 2016-04-07 University Of Ottawa Markers for inflammatory bowel disease
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
JP7576293B2 (ja) * 2017-01-13 2024-10-31 アイカーン スクール オブ メディシン アット マウント サイナイ ファーバー病を治療するための組成物及び方法
WO2022190064A1 (en) * 2021-03-12 2022-09-15 Vexo Pharmaceuticals Dmcc Methods for identifying subjects with betacoronavirus infections who are at risk of acute respiratory syndrome and methods for the treatment of same

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
CH585793A5 (da) 1974-02-01 1977-03-15 Nestle Sa
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
JPS5322158B2 (da) 1974-05-02 1978-07-06
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
IT1130242B (it) 1980-02-01 1986-06-11 Anic Spa Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5382524A (en) 1990-10-24 1995-01-17 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-n-acetylgalactosaminidase
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5433946A (en) 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JPH08505619A (ja) 1992-12-30 1996-06-18 ジョー レビス，ジョージ 抗虫歯組成物
EP0706374B1 (en) 1993-06-30 1997-12-10 Genentech, Inc. Method for preparing liposomes
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5997861A (en) 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
AU753303B2 (en) 1998-03-10 2002-10-17 Trustees Of The University Of Pennsylvania, The Enhancement of intracellular delivery and tissue targeting of drugs and genes
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US7018628B1 (en) 1998-07-24 2006-03-28 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
US6258581B1 (en) 1998-08-20 2001-07-10 Takara Shuzo Co., Ltd. Ceramidase gene
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
US6730297B1 (en) 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6767741B1 (en) 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
CA2387541A1 (en) 1999-10-13 2001-04-19 Yeda Research And Development Co. Ltd. Short segments of dap-kinase
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
US7850984B2 (en) 2000-02-15 2010-12-14 The General Hospital Corporation Protection of the female reproductive system from natural and artificial insults
AU2001253181A1 (en) 2000-04-06 2001-10-23 Exegenics, Inc. Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
ES2523856T3 (es) 2000-12-22 2014-12-02 Lpath, Inc. Anticuerpos de esfingosina-1-fosfato para el tratamiento de enfermedades asociadas con elevadas concentraciones de esfingolípidos
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
EP1234816B1 (de) 2001-02-23 2004-06-30 Biofrontera Pharmaceuticals GmbH Scyphostatin-Analoga als SMase-Inhibitoren
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
US7169610B2 (en) 2002-01-25 2007-01-30 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
WO2003086452A2 (en) 2002-04-05 2003-10-23 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
EP1431399A1 (en) 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
WO2004064750A2 (en) 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US10179935B2 (en) 2003-07-17 2019-01-15 Pacific Edge Limited Markers for detection of gastric cancer
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US7273756B2 (en) 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US8017394B2 (en) 2004-10-01 2011-09-13 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
WO2006050265A2 (en) 2004-10-29 2006-05-11 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
US7993868B2 (en) 2005-04-19 2011-08-09 Vermillion, Inc. Saposin D and FAM3C are biomarkers for alzheimer's disease
CN101282733A (zh) * 2005-08-03 2008-10-08 莫里亚生物制药公司 脂质结合物在囊性纤维化病中的用途及其应用
US20070162992A1 (en) 2006-01-09 2007-07-12 Mcgill University Metabolomic determination in assisted reproductive technology
AU2007209980A1 (en) 2006-01-27 2007-08-09 Eastern Virginia Medical School Proteomic fingerprinting of human IVF-derived embryos: identification of biomarkers of developmental potential
WO2007095688A1 (en) 2006-02-23 2007-08-30 The Australian National University Methods for increasing the number of circulating cells
DE602007008870D1 (de) * 2006-04-24 2010-10-14 Amc Amsterdam Verbessertes verfahren zur behandlung von cystischer fibrose
WO2007136635A1 (en) 2006-05-16 2007-11-29 Musc Foundation For Research Development Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators
EP2924440A3 (en) 2006-06-07 2016-03-09 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
AU2007261530B2 (en) 2006-06-20 2014-02-06 Genzyme Corporation Serum-free media and their uses for chondrocyte expansion
AU2008204982A1 (en) * 2007-01-05 2008-07-17 Mount Sinai School Of Medicine Acid ceramidase and cell survival
SI2132562T1 (sl) 2007-04-06 2012-05-31 Genzyme Corp Metode za ovrednotenje celic in celičnih kultur
EP2164875A4 (en) 2007-05-24 2011-11-30 Us Dept Veterans Affairs INTRANUCLEAR PROTEIN TRANSDUCTION THROUGH A NUCLEOSIDE SALVAGE PATHWAY
ES2583527T3 (es) 2007-05-31 2016-09-21 Paradigm Biopharmaceuticals Limited Xilanos sulfatados para el tratamiento o la profilaxis de enfermedades respiratorias
FR2924946B1 (fr) 2007-12-18 2010-02-26 Oreal Utilisation cosmetique de proteines de type ceramidase acide
DE102007063535A1 (de) * 2007-12-21 2009-06-25 Cycnad Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose
ES2385735T3 (es) 2008-06-26 2012-07-31 Orphazyme Aps Uso de Hsp70 como regulador de la actividad enzimática
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
JP5721631B2 (ja) * 2008-11-06 2015-05-20 ムスク ファウンデーション フォー リサーチ デベロップメント 酸性セラミダーゼのリソソーム親和性阻害剤
WO2010127355A1 (en) 2009-05-01 2010-11-04 Mount Sinai School Of Medicine Method to determine embryo and oocyte quality based on ceramidase
BR112012004377A2 (pt) 2009-08-28 2017-12-12 Genzyme Corp terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida.
CN102647905B (zh) 2009-10-19 2015-09-09 阿米库斯治疗学公司 用于预防和/或治疗溶酶体贮积失调的新颖组合物
MX381242B (es) 2009-11-27 2025-03-12 Genzyme Corp Una forma amorfa y una cristalina de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa.
WO2012051415A2 (en) 2010-10-13 2012-04-19 Mount Sinai School Of Medicine Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies
WO2013101276A2 (en) 2011-04-01 2013-07-04 Mount Sinai School Of Medicine Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway
EP2707724A4 (en) 2011-05-10 2015-01-21 Advanced Liquid Logic Inc ENZYME CONCENTRATION AND ASSAYS FOR THIS
JP6175431B2 (ja) 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法
WO2013036875A1 (en) 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation
EP3679923B1 (en) * 2012-06-01 2021-08-04 Icahn School of Medicine at Mount Sinai Ceramide levels in the treatment and prevention of infections
EP3659619A1 (en) 2013-03-14 2020-06-03 Icahn School of Medicine at Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them

Also Published As

Publication number Publication date
EP2854910B1 (en) 2020-04-15
WO2013181530A1 (en) 2013-12-05
US20220202919A1 (en) 2022-06-30
PT2854910T (pt) 2020-05-06
JP6639574B2 (ja) 2020-02-05
CN104582770A (zh) 2015-04-29
US20190151424A1 (en) 2019-05-23
US9492514B2 (en) 2016-11-15
US10159724B2 (en) 2018-12-25
US20170020998A1 (en) 2017-01-26
JP2020050668A (ja) 2020-04-02
JP2018162303A (ja) 2018-10-18
EP3679923A1 (en) 2020-07-15
CN104582770B (zh) 2019-01-29
EP2854910A4 (en) 2016-02-24
LT2854910T (lt) 2020-05-25
ES2786128T3 (es) 2020-10-08
US20150125439A1 (en) 2015-05-07
EP2854910A1 (en) 2015-04-08
ES2897825T3 (es) 2022-03-02
EP3679923B1 (en) 2021-08-04
US20250186565A1 (en) 2025-06-12
CA2874146A1 (en) 2013-12-05
HUE051020T2 (hu) 2021-01-28
SI2854910T1 (sl) 2020-09-30
CA2874146C (en) 2023-03-21
HRP20200661T1 (hr) 2020-10-30
JP2015518054A (ja) 2015-06-25
JP6369814B2 (ja) 2018-08-08
JP2025102904A (ja) 2025-07-08
PL2854910T3 (pl) 2020-07-27
CN109529028A (zh) 2019-03-29
JP2023021305A (ja) 2023-02-10

Similar Documents

Publication Publication Date Title
DK2882496T3 (da) Behandling og diagnosticering af melanom
DK2854910T3 (da) Ceramidniveauer i behandling og forebyggelse af infektioner
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2882441T3 (da) Behandling af immunrelaterede og inflammatoriske sygdomme
DK3335709T3 (da) Gamma-hydroxybutyratsammensætninger og deres anvendelse til behandling af lidelser
DK2774616T3 (da) Anvendelse af roseburia i behandling og forebyggelse af fedmerelaterede sygdomme
DK3346008T3 (da) Rekombinante mikroorganismer og anvendelser deraf
PT2714036T (pt) Alifanos, ciclofanos, heterafanos, heterofanos, heteroheterafanos e metalocenos substituídos úteis no tratamento de infeções hcv
DK2964255T3 (da) Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
LT2885010T (lt) Tautopatijos gydymo būdai
DK2844282T3 (da) Prostata-associerede antigener og vaccine-baserede immunterapiregimener
DK2776567T3 (da) Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK2723347T3 (da) Forebyggelse og behandling af inflammationstilstande
DK3838271T3 (da) Behandling af forhøjede niveauer af eosinophiler og/eller basophiler
DK2688557T3 (da) Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
GB201320723D0 (en) Composition and methods of treatment
DK3076972T3 (da) Cancerbehandling med kombination af plinabulin og taxan
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
HRP20181458T1 (hr) Protusmisleni polinukleotidi za induciranje preskakanja egzona i postupci liječenja distrofija
EP2818054A4 (en) METHOD FOR COOKING STEAM NOODLES AND DEVICE FOR COOKING STEAM NOODLES
BR112014031086A2 (pt) tratamento e prevenção de doenças cardiovasculares e trombose
DK2914261T3 (da) Syntetisk letalitet og behandling af cancer
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
DK3033081T3 (da) Sammensætninger og fremgangsmåder til behandling af kronisk urticaria